Amgen Inc. (NASDAQ:AMGN) is Edmp Inc.’s 4th Largest Position

Edmp Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.4% in the 1st quarter, Holdings Channel.com reports. The firm owned 16,335 shares of the medical research company’s stock after selling 64 shares during the period. Amgen comprises approximately 4.3% of Edmp Inc.’s portfolio, making the stock its 4th biggest holding. Edmp Inc.’s holdings in Amgen were worth $5,089,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in AMGN. Brighton Jones LLC increased its holdings in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares in the last quarter. World Equity Group Inc. grew its stake in Amgen by 19.7% in the 4th quarter. World Equity Group Inc. now owns 983 shares of the medical research company’s stock valued at $256,000 after acquiring an additional 162 shares during the period. Union Bancaire Privee UBP SA acquired a new stake in Amgen in the 4th quarter valued at $694,000. IFP Advisors Inc grew its stake in Amgen by 6.2% in the 4th quarter. IFP Advisors Inc now owns 6,102 shares of the medical research company’s stock valued at $1,591,000 after acquiring an additional 357 shares during the period. Finally, Pine Valley Investments Ltd Liability Co grew its stake in Amgen by 4.3% in the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 4,913 shares of the medical research company’s stock valued at $1,280,000 after acquiring an additional 204 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on AMGN shares. Johnson Rice set a $294.00 price target on shares of Amgen in a research note on Wednesday, March 5th. Guggenheim started coverage on shares of Amgen in a research note on Tuesday, May 20th. They set a “neutral” rating and a $288.00 target price on the stock. Bank of America lifted their target price on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research note on Wednesday, March 5th. Mizuho lifted their target price on shares of Amgen from $235.00 to $280.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 7th. Finally, Royal Bank Of Canada lowered their target price on shares of Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $309.22.

Insider Activity at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the business’s stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the sale, the senior vice president now directly owns 8,162 shares in the company, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.69% of the stock is owned by insiders.

Amgen Trading Up 1.9%

Shares of AMGN stock opened at $277.49 on Wednesday. The company’s 50-day moving average price is $281.03 and its 200-day moving average price is $286.04. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. The stock has a market cap of $149.21 billion, a price-to-earnings ratio of 25.32, a PEG ratio of 2.46 and a beta of 0.51. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to analysts’ expectations of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.96 EPS. As a group, equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.